Rivus posts a win for its experimental obesity drug in heart failure patients

Rivus Pharmaceuticals’ experimental cardiometabolic drug, HU6, nailed a mid-stage trial in obese patients with heart failure, finding that patients notched a statistically significant reduction in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Memory and forgetting are key to social learning, study suggests

One of the most actively debated questions about human and non-human culture is this: under what circumstances might we expect culture, in particular the ability

August 8, 2023

Sarepta discontinues next-generation Duchenne drugs

This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. The need-to-know this morning What

November 7, 2024

To secure the U.S.’s biotech supply chain, pay attention to domestic companies

Scientific breakthroughs will enable a future of personalized drug discovery, where precision medicine makes it possible to receive the right dose of the right medicine

June 28, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.